A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 26
Summary
- Conditions
- Carcinoma, Hepatocellular
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03418922
- Collaborators
- Ono Pharmaceutical Co. Ltd
- Investigators
- Not Provided
Get Well Soon